Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses Novartis’ hypertension treatment, Tekturna, which Speedel developed, as well as the benefits of other renin inhibitors in the Swiss biotech’s pipeline.
You may also be interested in...
Novartis Plans To Buy Back Speedel For $880 Million
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.
Novartis Plans To Buy Back Speedel For $880 Million
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.